ArticleJournal of clinical pharmacology2017

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.

Angela W Dymond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.